The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is planned to last about 12 months for each person. It compares the two inhaled medicines in a random way, and the treatment is given through an inhaler. During the study, asthma symptoms and general control of asthma are checked at several visits, and the treatment is continued while these checks are done. The main purpose of the study is to see whether Trimbow works at least as well as Fostair for asthma control.

The study also looks at how often people have worse asthma attacks, how often they need steroid tablets by mouth, and whether breathing and quality of life change during the study. Safety is also watched throughout the treatment period.

The purpose of the study is to see whether adding GB-0895 can lower the number of serious asthma attacks over a one‑year period. Volunteers will receive the assigned injection at regular intervals for about 52 weeks and will attend routine visits where doctors will check lung function using simple breathing tests, ask about daily symptoms, and have participants fill out questionnaires that measure how asthma affects daily life and overall well‑being. Terms such as “subcutaneous” mean the medication is delivered under the skin, and “systemic corticosteroids” refer to steroid medicines taken by mouth or injection that help reduce inflammation during severe attacks.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

The purpose of this study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo, which is a substance with no active medication. The study will last for about 12 months, during which participants will receive regular injections and have their triglyceride levels monitored at various points to see how they change over time.

Throughout the study, participants will be closely monitored for any changes in their health and any side effects they might experience. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to see if it helps more participants reach healthier triglyceride levels. This research could lead to a new treatment option for people with severe hypertriglyceridemia, potentially improving their health and reducing the risk of complications associated with high triglyceride levels.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The treatment will be given as an subcutaneous injection (an injection under the skin). The medication or placebo will be administered over several weeks, with participants being monitored for a total of 16 weeks. The maximum daily dose of NGM120 will be 200 milligrams, with a total maximum dose of 2000 milligrams over the course of treatment.

Throughout the study, participants will be evaluated for changes in their body weight and overall health status. The study will also look at how well the body tolerates NGM120 and track any side effects that may occur. Various aspects of participants’ well-being will be monitored, including their fatigue levels, physical function, appetite, and ability to perform daily activities.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

Participants in the study will receive either the test medication NNC0662-0419, a comparator drug named Ozempic, or a placebo. The study will monitor changes in HbA1c, which is a blood test that shows the average blood sugar levels over the past few months. Additionally, changes in body weight will be observed during the course of the research.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.

Participants in this study are individuals who have previously taken part in other clinical trials involving the medication. During this phase, participants may be placed in an observation group to monitor their condition over time, or they may receive retreatment with barzolvolimab. The study follows participants for up to 52 weeks to observe how well the disease is controlled and to monitor for any adverse events, which are unintended or harmful medical occurrences that may happen during the course of treatment.

Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

Participants will be assigned to different groups to receive either orforglipron or a placebo once daily by oral use. During the study, the ability to walk a certain distance will be monitored to see how the medication affects movement and physical activity over time.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.

The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.

The purpose of this research is to evaluate how safe the medication is and how well patients tolerate it when used for a longer period. The medication is given as a subcutaneous injection (under the skin) using a pre-filled syringe. This is an open-label extension study, which means all participants will receive the actual medication, and it continues treatment for patients who completed an earlier study called Lp(a)HORIZON.

During the study, participants will receive regular doses of pelacarsen for up to 36 months. The maximum daily dose is 80 milligrams. The study will monitor participants’ health through regular check-ups and blood tests to ensure their safety while taking the medication. Researchers will track various health measurements and any side effects that may occur during the treatment period.

The purpose of this research is to assess how safe and well-tolerated NBI-1065845 is when taken as an additional treatment alongside regular antidepressant medication. The study medication comes in the form of oral tablets that participants take along with their current antidepressant treatment.

This is a long-term study that lasts for approximately 52 weeks (one year). During this time, all participants receive the study medication NBI-1065845 while continuing their current antidepressant treatment at the same dose they were taking before joining the study. The study team monitors participants’ health and any side effects that may occur throughout the treatment period.

The purpose of this research is to understand how different doses of GHZ339 work compared to placebo in treating atopic dermatitis, specifically looking at how much the skin condition improves after 16 weeks of treatment. The study is designed as a platform trial, which means it will test multiple treatments simultaneously.

During the study, participants will receive either GHZ339 injections or placebo injections, along with various topical medications that are applied directly to the skin. The treatment period will last for several months, during which participants will have regular check-ups to monitor their skin condition and overall health. The effectiveness of the treatment will be measured by examining changes in the severity and extent of skin inflammation.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The purpose of this research is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels after 12 weeks of treatment. The medication comes as a film-coated tablet that is taken by mouth. Some participants will receive AZD0780, while others will receive a placebo.

The study will last for 52 weeks (one year), during which participants will continue taking their regular cholesterol-lowering medications. Throughout the study, researchers will measure various types of cholesterol and other blood fats, including apolipoprotein B, non-HDL cholesterol, and lipoprotein(a), to understand how well the treatment works.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of the study is to evaluate how safe plozasiran is for long-term use in people with hypertriglyceridemia. Participants in the study will receive injections of plozasiran and will be monitored over time to see how their triglyceride levels change. The study will also look at other factors, such as changes in cholesterol levels and any side effects that may occur during the treatment period.

Throughout the study, participants will have regular check-ups to track their health and any changes in their condition. The study aims to provide valuable information on the safety and potential benefits of plozasiran for managing high triglyceride levels in the long term. This research could help improve treatment options for individuals with hypertriglyceridemia.

The trial involves comparing the effects of ITI-1284 with a placebo, which looks like the real medication but does not contain the active ingredient. Participants in the study will take the medication once daily for a period of six weeks. During this time, researchers will monitor changes in the participants’ symptoms to determine how well the medication works in reducing the symptoms of psychosis.

The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The goal is to provide a clearer understanding of the potential benefits and safety of ITI-1284 for individuals with psychosis related to Alzheimer’s disease.

The purpose of the study is to evaluate how well seltorexant works when used alongside other antidepressants, specifically those known as SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors). The study will compare the effects of taking seltorexant with a placebo, which looks like the medication but does not contain the active ingredient. The study aims to see if seltorexant can improve depressive symptoms and help maintain these improvements over time.

Participants in the study will take part in two main parts. In the first part, the effectiveness of seltorexant in improving symptoms of depression will be assessed. In the second part, the focus will be on whether seltorexant can help prevent the return of depressive symptoms after initial improvement. The study will involve taking the medication in the form of a film-coated tablet by mouth. The trial is designed to ensure the safety and effectiveness of seltorexant as an additional treatment for those who have not fully responded to their current antidepressant therapy.